IMARC Group's latest report, titled “Blood Plasma Derivatives Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028," finds that the global blood plasma derivatives market size reached US$ 43.2 Billion in 2022. Blood plasma derivatives are concentrated forms of specific proteins made from plasma collected through fractionation. They are commonly used to kill viruses that cause hepatitis B, hemophilia A, bleeding disorders, immunodeficiency, hepatitis C, hypogammaglobulinemia, hemophilia B, and human immunodeficiency virus (HIV), as they are rich in proteins, minerals, salts, hormones, vitamins, and protease inhibitors. Some commonly used blood plasma derivatives include factor VIII, immunoglobulin, albumin, hyperimmune globulin, factor IX, and fresh frozen. They help improve nutrition, control body temperature and blood clotting, maintain osmotic pressure, enhance respiration and excretion, and control acid-base balance. At present, blood plasma derivatives are commonly stored at diagnostic centers, hospitals, clinics, and blood transfusion centers across the globe.
Global Blood Plasma Derivatives Market Trends:
The rising prevalence of infectious diseases and the expanding geriatric population represent the primary factors driving the market growth. Moreover, the surging adoption of blood plasma derivatives to treat coronavirus disease (COVID-19) patients by convalescent plasma treatment is positively influencing the market growth. Apart from this, numerous technological advancements in the fractionation process that help separate blood plasma components and protein concentrates for clinical use are propelling the market growth. Additionally, continual improvements in existing procedures and the development of novel preservation techniques to produce targeted therapeutic products are other major growth-inducing factors. Besides this, the escalating demand for blood plasma derivatives due to the rise in the prevalence of life-threatening diseases, such as immunodeficiency disorders and hemophilia, has catalyzed market growth. This can be attributed to the presence of immunoglobins in blood plasma that are essential for the development of immunity and for maintaining the osmotic pressure in blood vessels, which further slows the onset of hemophilia and immune deficiency disorders. Other factors, including the rising awareness regarding blood and plasma donation, favorable government initiatives to promote blood donation camps, and rapid growth in the healthcare industry, are also anticipated to create a positive market outlook. Looking forward, IMARC Group expects the market value to reach US$ 61.9 Billion by 2028, expanding at a CAGR of 6.1% during 2023-2028.
- On the basis of the type, the market has been divided into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others.
- Based on the application, the market has been segmented into hemophilia, hypogammaglobulinemia, immunodeficiency diseases, Von Willebrand’s disease, and others.
- The market has been categorized based on the end user into hospitals, clinics, and others.
- Region-wise, the market has been segregated into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others) and Middle East and Africa.
- The competitive landscape of the market has also been analyzed, with some of the key players being Baxter International Inc., Bayer AG, CSL Limited, Fusion Health Care Pvt. Ltd., Grifols S.A., Kedrion S.p.A., LFB S.A., Octapharma AG, Sanofi S.A., and Takeda Pharmaceutical Company Limited.
|Base Year of the Analysis
||Type, Application, End User, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Baxter International Inc., Bayer AG, CSL Limited, Fusion Health Care Pvt. Ltd., Grifols S.A., Kedrion S.p.A., LFB S.A., Octapharma AG, Sanofi S.A. and Takeda Pharmaceutical Company Limited
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N A
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800